Twinlab Reports 37% Decline in Q3 2024 Net Sales, Faces Financial Challenges

Twinlab Consolidated Holdings, Inc. reported a significant decline in financial performance for the third quarter of 2024, with net sales dropping to $2.3 million, a decrease of 37% compared to $3.7 million in the same period last year. For the nine months ending September 30, 2024, total revenue was $8.2 million, down 22% from $10.5 million in 2023. The company's gross profit also fell sharply, recording $642,000 for the quarter, down 52% year-over-year, and $2.7 million for the nine-month period, a 32% decline. The decrease in sales and gross profit was attributed primarily to supply chain issues affecting high-margin products.

Operating expenses showed mixed results, with selling expenses decreasing by 63% for both the three and nine-month periods, reflecting reduced advertising and marketing costs. Conversely, general and administrative expenses increased by 6% in the third quarter, largely due to lease impairments, but decreased by 18% over the nine months, driven by lower salaries and operational costs. The company reported a loss from operations of $746,000 for the third quarter, compared to a loss of $202,000 in the prior year, and a total net loss of $2.7 million for the quarter, which was an improvement from a loss of $5.4 million in the same period last year.

Twinlab's balance sheet as of September 30, 2024, showed total assets of $7.6 million, down from $9.0 million at the end of 2023. Current liabilities increased to $151.6 million, primarily due to a rise in accrued interest. The company reported a working capital deficiency of $146.6 million and an accumulated deficit of $376.5 million, raising concerns about its ability to continue as a going concern. Management is focusing on core business growth, negotiating lower supplier prices, and may need to raise additional capital through debt or equity offerings.

In terms of operational developments, Twinlab has ceased operations of its subsidiary, NutraScience Labs, which contributed to a loss of $1.2 million in the previous year. The company is now concentrating on its core brands, including Twinlab, Reserveage, and ResVitale, and has streamlined its product offerings to approximately 70 stock keeping units (SKUs). The company’s strategic focus includes enhancing customer relationships and product innovation to regain market share.

Looking ahead, Twinlab's management acknowledges the need for additional funding to support operations and execute its business plan. The company is exploring various financing options, including equity offerings and strategic partnerships, but faces uncertainty regarding the availability of these funds. The ongoing challenges in the supply chain and the need for operational restructuring may impact the company's recovery and growth trajectory in the near term.